Sionna Therapeutics

Sionna was founded in 2019 and is advancing a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is defective in cystic fibrosis by stabilizing CFTR’s first nucleotide-binding domain (NBD1).

Headquarters Boston, MA
Pipeline Preclinical
Twitter @sionna_tx
LinkedIn Sionna Therapeutics